e-learning
resources
2020
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis
Brian D. Kent, Grainne d'Ancona, Mariana Fernandes, Linda Green, Cris Roxas, Louise Thomson, Alexandra M. Nanzer, Joanne Kavanagh, Sangita Agarwal, David J. Jackson
Source:
ERJ Open Res, 6 (1) 00311-2019; 10.1183/23120541.00311-2019
Journal Issue:
January
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Brian D. Kent, Grainne d'Ancona, Mariana Fernandes, Linda Green, Cris Roxas, Louise Thomson, Alexandra M. Nanzer, Joanne Kavanagh, Sangita Agarwal, David J. Jackson. Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res, 6 (1) 00311-2019; 10.1183/23120541.00311-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
Source: ERJ Open Res, 6 (4) 00451-2020; 10.1183/23120541.00451-2020
Year: 2020
Mepolizumab as a steroid-sparing agent for eosinophilic granulomatosis with poliangiitis: a case series
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019
Biologics for eosinophilic granulomatosis with polyangiitis
Source: Short video statement 2020
Year: 2020
Wegener's granulomatosis after Montelukast in patient not receiving systemic steroid treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 65s
Year: 2002
Eosinophilic granulomatosis with polyangiitis
Source: Eur Respir Monogr 2019; 86: 188-209
Year: 2019
Eosinophilic granulomatosis with polyangiitis
Source: Eur Respir Monogr 2022; 95: 177-192
Year: 2022
Frequency of eosinophilic granulomatosis with polyangiitis in Europe by meta-analysis
Source: Virtual Congress 2020 – Prevalence and incidence of chronic lung diseases
Year: 2020
ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) relatead to sirolimus-eluting stent
Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects
Year: 2015
Granulomatosis with polyangiitis (Wegener&s)
Source: Eur Respir Mon 2011; 54: 1-14
Year: 2011
New biomarkers for early diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA)
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab
Source: Eur Respir J 2006; 27: 644-646
Year: 2006
Lung-limited Granulomatosis with polyangiitis (GPA) managed without immunosuppression
Source: International Congress 2018 – CC5 Pulmonary vasculitis: the great chameleon
Year: 2018
Twelve month outcomes with Reslizumab treatment of Eosinophilic Granulomatosis with Polyangiitis
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Effectiveness of rituximab (RTX) therapy in recurrent granulomatosis with polyangiitis (GPA)
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
Aerosolized tobramycin in patients with Wegener's granulomatosis
Source: Eur Respir J 2001; 18: Suppl. 33, 138s
Year: 2001
Pulmonary hypertension as the first manifestation in a patient with granulomatosis with polyangiitis
Source: International Congress 2019 – Pulmonary vascular diseases?
Year: 2019
Microscopic polyangiitis and granulomatosis with polyangiitis
Source: Eur Respir Monogr 2019; 86: 153-172
Year: 2019
Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
Source: Eur Respir J 2016; 48: 1429-1441
Year: 2016
Different disease subtypes in allergic eosinophilic granulomatosis with polyangiitis (EGPA)
Source: Annual Congress 2013 –Clinical management of orphan lung diseases
Year: 2013
The role of intratracheal dilation – Injection technique in treatment of granulomatosis with polyangiitis (GPA) patients with subglottic stenosis
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept